Summary of Classification and Labelling
General Information
EC / List no.
|
Name |
CAS Number
|
|---|---|---|
| 682-137-1 | (3-((4-benzoyl-1-piperazinyl)(oxo)acetyl)-4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)methyl dihydrogen phosphate | 864953-39-9 |
Notified classification and labelling according to CLP criteria
| Classification | Labelling | Specific Concentration limits, M-Factors | Notes | Classification affected by Impurities / Additives
|
Additional Notified Information
|
Number of Notifiers
|
Joint Entries
|
||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Class and Category Code(s) | Hazard Statement Code(s) | Hazard Statement Code(s) | Supplementary Hazard Statement Code(s) | Pictograms, Signal Word Code(s) | |||||||
| Skin Sens. 1B | H317 | H317 |
GHS08 GHS07 Wng |
State/Form
|
3 | View details | |||||
| Repr. 2 | H361 | H361 | |||||||||
| STOT RE 2 | H373 (adrenal glands,...) | H373 | |||||||||
| Skin Sens. 1 | H317 | H317 |
GHS08 Dgr |
State/Form
|
1 | View details | |||||
| STOT RE 2 | H373 (immune system) | H373 | |||||||||
| Skin Sens. 1B | H317 | H317 |
GHS08 GHS07 Wng |
State/Form
|
1 | View details | |||||
| STOT RE 2 | H373 (Adrenal glands,...) | H373 | |||||||||
| STOT RE 2 | H373 (other:Adrenal g...) | H373 | |||||||||
| Skin Sens. 1B | H317 | H317 |
GHS08 GHS07 Wng |
1 | View details | ||||||
| STOT RE 2 | H373 (abdominal cavit...) | H373 | |||||||||
Number of Aggregated Notifications: 4